Weight loss is a committed journey that requires one to be dedicated and show consistency. But with social media, every other person suggesting new diet and workout plans, it's not uncommon to get ...

At the pace with which the proportion of overweight people is growing, half of Nepal’s adult population will be obese by 2050 ...

Prescription medication costs are forcing some hard choices for many Nevadans. Two years ago, a proposal that offered hope sailed through the Democrat-majority Nevada Legislature only to be vetoed ...

How weight loss drugs actually work, and how big-name prescriptions differ from each other. What investors need to know about ...

Viking Therapeutics inks broad manufacturing pact with CordenPharma to support commercialization of VK2735: San Diego Wednesday, March 12, 2025, 17:00 Hrs [IST] Viking Therapeutic ...

with the former currently leading the charge with a phase 3 readout for its oral semaglutide for obesity due in the first quarter of 2024. The drug is already approved as Rybelsus for type 2 diabetes.

Roche has reported early-stage clinical data with an oral GLP-1 agonist acquired as part of its $3.1 billion takeover ... of semaglutide for diabetes – Rybelsus – needs to be dosed in the ...

Many are in the chase of quick fixes in weight loss, but more than often it's ineffective. Expert debunks 6 common weight loss myths.

Semaglutide use in patients with type 2 diabetes moderately increases the risk of nonarteritic anterior ischemic optic neuropathy.